These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 18981291)

  • 1. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP.
    Bussel JB; Kuter DJ; Pullarkat V; Lyons RM; Guo M; Nichol JL
    Blood; 2009 Mar; 113(10):2161-71. PubMed ID: 18981291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II, open-label, sequential-cohort, dose-escalation study of romiplostim in Japanese patients with chronic immune thrombocytopenic purpura.
    Shirasugi Y; Ando K; Hashino S; Nagasawa T; Kurata Y; Kishimoto Y; Iwato K; Ohtsu T; Berger DP
    Int J Hematol; 2009 Sep; 90(2):157-165. PubMed ID: 19543952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial.
    Kuter DJ; Bussel JB; Lyons RM; Pullarkat V; Gernsheimer TB; Senecal FM; Aledort LM; George JN; Kessler CM; Sanz MA; Liebman HA; Slovick FT; de Wolf JT; Bourgeois E; Guthrie TH; Newland A; Wasser JS; Hamburg SI; Grande C; Lefrère F; Lichtin AE; Tarantino MD; Terebelo HR; Viallard JF; Cuevas FJ; Go RS; Henry DH; Redner RL; Rice L; Schipperus MR; Guo DM; Nichol JL
    Lancet; 2008 Feb; 371(9610):395-403. PubMed ID: 18242413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP).
    Bussel JB; Hsieh L; Buchanan GR; Stine K; Kalpatthi R; Gnarra DJ; Ho RH; Nie K; Eisen M
    Pediatr Blood Cancer; 2015 Feb; 62(2):208-213. PubMed ID: 25345874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP.
    Bussel JB; Kuter DJ; George JN; McMillan R; Aledort LM; Conklin GT; Lichtin AE; Lyons RM; Nieva J; Wasser JS; Wiznitzer I; Kelly R; Chen CF; Nichol JL
    N Engl J Med; 2006 Oct; 355(16):1672-81. PubMed ID: 17050891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim.
    Kuter DJ; Mufti GJ; Bain BJ; Hasserjian RP; Davis W; Rutstein M
    Blood; 2009 Oct; 114(18):3748-56. PubMed ID: 19671919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Romiplostim: a review of its use in immune thrombocytopenia.
    Keating GM
    Drugs; 2012 Feb; 72(3):415-35. PubMed ID: 22316355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Romiplostim: a novel thrombopoiesis-stimulating agent.
    Perreault S; Burzynski J
    Am J Health Syst Pharm; 2009 May; 66(9):817-24. PubMed ID: 19386944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open-label extension study evaluating the safety and efficacy of romiplostim for up to 3.5 years in thrombocytopenic Japanese patients with immune thrombocytopenic purpura (ITP).
    Shirasugi Y; Ando K; Miyazaki K; Tomiyama Y; Iwato K; Okamoto S; Kurokawa M; Kirito K; Hashino S; Ninomiya H; Mori S; Yonemura Y; Usuki K; Wei H; Lizambri R
    Int J Hematol; 2012 Jun; 95(6):652-9. PubMed ID: 22532046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia.
    Bussel JB; Buchanan GR; Nugent DJ; Gnarra DJ; Bomgaars LR; Blanchette VS; Wang YM; Nie K; Jun S
    Blood; 2011 Jul; 118(1):28-36. PubMed ID: 21502541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: focus on romiplostim and eltrombopag.
    Chouhan JD; Herrington JD
    Pharmacotherapy; 2010 Jul; 30(7):666-83. PubMed ID: 20575632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura.
    Newland A; Caulier MT; Kappers-Klunne M; Schipperus MR; Lefrere F; Zwaginga JJ; Christal J; Chen CF; Nichol JL
    Br J Haematol; 2006 Nov; 135(4):547-53. PubMed ID: 17061981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Romiplostim in chronic immune thrombocytopenic purpura.
    Cersosimo RJ
    Clin Ther; 2009 Sep; 31(9):1887-907. PubMed ID: 19843480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia.
    Tarantino MD; Bussel JB; Blanchette VS; Beam D; Roy J; Despotovic J; Raj A; Carpenter N; Mehta B; Eisen M
    Haematologica; 2019 Nov; 104(11):2283-2291. PubMed ID: 30846500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet production bolstered with romiplostim approval.
    Morrow T
    Manag Care; 2008 Oct; 17(10):49-50. PubMed ID: 18990926
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials.
    Rodeghiero F; Stasi R; Giagounidis A; Viallard JF; Godeau B; Pabinger I; Cines D; Liebman H; Wang X; Woodard P
    Eur J Haematol; 2013 Nov; 91(5):423-36. PubMed ID: 23927437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Romiplostim Treatment in Adults with Immune Thrombocytopenia of Varying Duration and Severity.
    Janssens A; Tarantino M; Bird RJ; Mazzucconi MG; Boccia RV; Fernández MF; Kozak T; Steurer M; Boekhorst Pt; Dillingham K; Kreuzbauer G; Woodard P
    Acta Haematol; 2015; 134(4):215-28. PubMed ID: 26066765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program.
    Khellaf M; Michel M; Quittet P; Viallard JF; Alexis M; Roudot-Thoraval F; Cheze S; Durand JM; Lefrère F; Galicier L; Lambotte O; Panelatti G; Slama B; Damaj G; Sebahoun G; Gyan E; Delbrel X; Dhedin N; Royer B; Schleinitz N; Rossi JF; Mahévas M; Languille L; Bierling P; Godeau B
    Blood; 2011 Oct; 118(16):4338-45. PubMed ID: 21832276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial.
    Shirasugi Y; Ando K; Miyazaki K; Tomiyama Y; Okamoto S; Kurokawa M; Kirito K; Yonemura Y; Mori S; Usuki K; Iwato K; Hashino S; Wei H; Lizambri R
    Int J Hematol; 2011 Jul; 94(1):71-80. PubMed ID: 21706145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A single-arm, long-term efficacy and safety study of subcutaneous romiplostim in children with immune thrombocytopenia.
    Grainger J; Bussel J; Tarantino M; Cooper N; Beam D; Despotovic J; Maschan A; Wang K; Eisen M; Bowers C
    Blood Adv; 2023 Feb; 7(3):396-405. PubMed ID: 35413092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.